Related Experiment Video
Updated: Aug 23, 2025
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
Oncolytic virus preclinical toxicology studies
Agnija Rasa1, Pēteris Alberts1
1R&D, Rigvir, Riga, Latvia.
Abstract:
With the ever-emerging concerns of patient safety during medical care, the search for treatments as safe as possible is a priority, especially when focusing on cancer treatment of which therapies often go hand in hand with severe side effects. Oncolytic virotherapy is an emerging treatment for cancer that is promising in both safety and efficacy. Many currently ongoing clinical trials demonstrate the growing interest in this field. To conduct clinical trials, preclinical studies are mandatory; however, there are not many reviews of toxicology studies on oncolytic virus therapies. This article summarizes the preclinical toxicology studies of the most well studied oncolytic viruses, including Oncorine, Talimogene laherparepvec, Cavatak, ONYX-015, teserpaturev and Rigvir, a non-pathogenic ECHO-7 virus. It is concluded that oncolytic viruses have been shown to have low toxicity and high tolerability in preclinical toxicology studies.
Insights
Oncolytic virotherapy shows promise for cancer treatment. Preclinical toxicology studies indicate that these oncolytic viruses are safe and well-tolerated, supporting their clinical trial progression.
Area of Science:
- Oncology
- Virology
- Toxicology
Background:
- Patient safety is paramount in cancer treatment due to severe side effects of conventional therapies.
- Oncolytic virotherapy presents a promising alternative with potential for both safety and efficacy.
- Growing interest in oncolytic virotherapy is evidenced by numerous ongoing clinical trials.
Purpose of the Study:
- To review and summarize preclinical toxicology studies of major oncolytic viruses.
- To assess the safety and tolerability profiles of these emerging cancer therapies.
Main Methods:
- Compilation and analysis of existing preclinical toxicology data for key oncolytic viruses.
- Inclusion of widely studied agents like Oncorine, Talimogene laherparepvec, Cavatak, ONYX-015, teserpaturev, and Rigvir (ECHO-7 virus).
Main Results:
- Preclinical toxicology studies consistently demonstrate low toxicity associated with oncolytic virus therapies.
- These viruses exhibit high tolerability in preclinical models, indicating a favorable safety margin.
Conclusions:
- Oncolytic viruses represent a safe and well-tolerated therapeutic strategy for cancer treatment.
- Favorable preclinical safety data supports the continued development and clinical application of oncolytic virotherapy.
Related Concept Videos
01:28Preclinical Development: Overview
01:25Mutagenicity and Carcinogenicity
01:16In-vitro Mutagenesis